Abstract | INTRODUCTION: METHODS: The open study included 21 patients with AD. EPO (4-6 g) was administered daily for 12 weeks. Before treatment, and 4 and 12 weeks after initiation of EPO supplementation, objective SCORAD was assessed and plasma concentrations of GLA and DGLA were determined by gas chromatography. RESULTS: A significant increase in plasma GLA and DGLA levels and a decrease in the objective SCORAD were observed 4 and 12 weeks after initiation of EPO treatment. In the per-protocol population (n = 14), a significant inverse correlation between the changes in plasma GLA levels and SCORAD was found (P = 0.008). CONCLUSION: The clinical disease activity under EPO treatment correlates with the individual increase in plasma GLA levels. Thus, the results of this pilot study indicate that an increase in plasma GLA might be used as predictive parameter for responsiveness of AD to EPO therapy.
|
Authors | Dagmar Simon, Peter A Eng, Siegfried Borelli, Roland Kägi, Christian Zimmermann, Catherine Zahner, Jürgen Drewe, Lorenzo Hess, Giovanni Ferrari, Stephan Lautenschlager, Brunello Wüthrich, Peter Schmid-Grendelmeier |
Journal | Advances in therapy
(Adv Ther)
Vol. 31
Issue 2
Pg. 180-8
(Feb 2014)
ISSN: 1865-8652 [Electronic] United States |
PMID | 24435467
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dermatologic Agents
- Linoleic Acids
- Plant Oils
- evening primrose oil
- gamma-Linolenic Acid
- 8,11,14-Eicosatrienoic Acid
|
Topics |
- 8,11,14-Eicosatrienoic Acid
(blood)
- Adolescent
- Adult
- Child
- Child, Preschool
- Cohort Studies
- Dermatitis, Atopic
(blood, drug therapy)
- Dermatologic Agents
(chemistry, therapeutic use)
- Female
- Humans
- Linoleic Acids
(chemistry, therapeutic use)
- Male
- Middle Aged
- Oenothera biennis
- Plant Oils
(chemistry, therapeutic use)
- Prospective Studies
- Treatment Outcome
- Young Adult
- gamma-Linolenic Acid
(analysis, blood, chemistry, therapeutic use)
|